Pluri (PLUR) Change in Accured Expenses (2010 - 2025)
Pluri (PLUR) posted quarterly Change in Accured Expenses of $903000.0 for Q4 2025, up 157.63% year-over-year from $350508.1 in Q4 2024, and up 320.24% quarter-over-quarter from -$410000.0 in Q3 2025.
Pluri (PLUR) Change in Accured Expenses (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported Change in Accured Expenses for 16 consecutive years, with $903000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses rose 157.63% year-over-year to $903000.0; the TTM figure through Dec 2025 stood at $1.1 million (up 179.35% YoY), while the FY2025 annual figure was $377000.0, up 231.36% from the prior year.
- Change in Accured Expenses grew to $903000.0 in Q4 2025 per PLUR's latest filing, from -$410000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.4 million in Q2 2021 and bottomed at -$3.0 million in Q2 2022.
- Historically, Change in Accured Expenses has averaged -$109950.0 across 5 years, with a median of -$27000.0 in 2022.
- Annual changes were most pronounced in 2021 — Change in Accured Expenses slumped 1775.0% — and 2023, when it soared 2172.22%.
- Pluri's Change in Accured Expenses stood at -$1.3 million in 2021, then surged by 104.03% to $54000.0 in 2022, then jumped by 2172.22% to $1.2 million in 2023, then tumbled by 227.71% to -$1.6 million in 2024, then soared by 157.63% to $903000.0 in 2025.
- Business Quant data shows PLUR's Change in Accured Expenses at $903000.0 in Q4 2025, -$410000.0 in Q3 2025, and -$544000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | -177,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 903,000.00 |
| Dec 31, 2025 | 903,000.00 |
| Sep 30, 2025 | -410,000.00 |
| Sep 30, 2025 | -410,000.00 |
| Jun 30, 2025 | -544,000.00 |
| Jun 30, 2025 | -544,000.00 |
| Mar 31, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | -1.57 Mn |
| Dec 31, 2024 | -1.57 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 168,000.00 |
| Jun 30, 2024 | 168,000.00 |
| Mar 31, 2024 | -1.32 Mn |
| Mar 31, 2024 | -1.32 Mn |
| Dec 31, 2023 | 1.23 Mn |
| Dec 31, 2023 | 1.23 Mn |
| Sep 30, 2023 | -358,000.00 |
| Sep 30, 2023 | -358,000.00 |